Research programme: lipid metabolism therapies - Catabasis Pharmaceuticals

Drug Profile

Research programme: lipid metabolism therapies - Catabasis Pharmaceuticals

Alternative Names: CAT 2000; CAT 3000

Latest Information Update: 17 Aug 2016

Price : $50

At a glance

  • Originator Catabasis Pharmaceuticals
  • Class Eicosanoids; Nicotinic-acids; Omega 3 fatty acids; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Cyclooxygenase inhibitors; Inflammation mediator inhibitors; Platelet aggregation inhibitors; Sterol regulatory element binding protein modulators; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dyslipidaemias; Hypertriglyceridaemia

Most Recent Events

  • 17 Aug 2016 Research progrqamme still in preclinical development for Dyslipidaemia and Hypertriglyceridaemia in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Dyslipidaemias in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Hypertriglyceridaemia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top